PanTher Therapeutics Receives FDA Clearance of IND Application for Phase IB Study of PTM-101 for the Localized Treatment of Pancreatic Cancer

PanTher Therapeutics, Inc. announced the US FDA clearance of the Investigational New Drug application for the company’s lead program, PTM-101, to proceed in a Phase IB clinical study in patients with PDAC.